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Abstract
Introduction: Monitoring antiretroviral therapy in resource limiting setting is crucial to
ensure successful treatment, identify adherence problems and determine whether ART
regimens should be switched in case of treatment failure. However, there remains to explore
more on predictors of time to treatment failure in second line ART and In addition to HIV
CD4 cell counts are influenced by other factors. Thus the motivation of this study was to
analyze jointly repeated measurements of CD4 cell count and time to treatment failure.
Objective: The objective of this study was to assess the change in CD4 cell count and time
to treatment failure as well as their risk factors from second line antiretroviral therapy among
adults in Amhara region.
Methods: A retrospective follow up study was conducted from February 2008 to 2016. All
adult patients who started second line ART from February 2008 to 2016 in eight selected
government hospitals of Amhara region were the population under study. Joint modeling
was employed and variables with p-value <0.05 is considered as significant predictors of the
change in CD4 cell count and time to treatment failure.
Result: The average rate of change in CD4 cell count was found 1.13 cells/ mm3 with
mean±SD of (-0.03, 2.29) per six months. The overall incidence rate of treatment failure was
found 9.88 per 100 person years and treatment failure was high during the first year. A
significant association (HR=0.173, 95%CI=0.129-0.232) was found between the current true
level of log CD4 cell count and time to treatment failure. Good ART adherence
(β=0.079,95%CI=0.011-0.148), modified regimens (β=0.105,95%CI 0.042-0.168),CD4 cell
count at switch (≤100 cells/ mm3) (β=-0.966, 95%CI=-1.035-(-0.896)) were found a
significant predictors for the change of log CD4 cell count, also taking INH
(HR=0.631,95%CI=0.455-0.876), HIV patients under second line  regimen TDF-3TC-
LPV/r(HR=1.841,95%CI=1.182-2.867),HIV patients under second line regimen AZT-3TC-
LPV/r(HR=2.76,95%CI=1.641-4.644) and CD4 at switch (≤100 cells/ mm3)(HR=2.795,
95%CI=1.983-3.939) were found a significant predictors of time to treatment failure.
Conclusion and Recommendation: In conclusion, low increase of average CD4 cell count
and higher incidence rate of treatment failure were obtained from second line ART among
adults in Amhara region. Good ART adherence , modified regimens, CD4 cell count at
switch(≤100 cells /mm3) were a significant predictors for the change of   log CD4 cell count,
whereas taking INH, second line regimenTDF-3TC-LPV/r , second line regimen AZT-3TC-
LPV/r , CD4 cell count at switch(≤100 cells /mm3)  were  found a significant predictors of
time to treatment failure. Therefore improving the ART Adherence, giving INH, modified
regimens shall be done.
Key words: CD4 cell count, treatment failure, joint modeling, Adults
11. Introduction
1.1 Statement of the problem
Antiretroviral therapy (ART) is a treatment for human immunodeficiency virus (HIV) positive
people who are using anti-HIV drugs. The standard treatment consists of a combination of at
least three drugs often called “highly active antiretroviral therapy (HAART)”, which suppress
HIV replication. ART dramatically reduced HIV-associated morbidity and mortality and has
transformed HIV infection in to a manageable chronic condition(1, 2).Coverage of ART at
the end of 2015 reached 46% globally and 54% for eastern and southern Africa. South
Africa and Kenya have the largest treatment program in Africa. The gains in ART are largely
responsible for a 26% decline in AIDS-related deaths globally since 2010, from an estimated
1.5 million in 2010 to 1.1 million in 2015(3).
In resource limited settings the proportion of patients on second line ART are estimated
between 1-5%(4). In Ethiopia 344,344 people were using ART, from these ART users, 1.5%
were on second-line treatment(5). For Adults and Adolescents 2NRTIs+ ATV/r or LPV/r and
2 NRTIs+ DRV/r are preferable and alternative second line regimens respectively(6).
One of the major concerns over the rapid scaling up of ART is the emergence of resistant
strains due to treatment failure. Treatment failure occurs when an antiretroviral (ARV)
regimen is unable to control viral progression and it can be clinical failure, immunologic
failure, Virologic failure, or any combination of the three. Where viral load monitoring is not
available, clinical monitoring and CD4 monitoring are recommended(7). Clinical failure for
adults and adolescents defined as new or recurrent clinical event indicating severe
immunodeficiency (WHO clinical stage 4 condition and certain WHO clinical stage 3
conditions (pulmonary TB and sever bacterial infections)) after 6 months of effective
treatment, also adults and adolescents who have  CD4 count at or below 250 cells/mm3
following clinical failure or Persistent CD4 levels below 100 cells/mm3 (6, 8) were
considered as experiencing immunological failure.
CD4 cell count is used to assess patient’s immunologic response to ART. For most patients
on therapy, an adequate response is defined as an increase in CD4 count in the range of 50
to150 cells/mm3 during the first year of ART, and the average increase is approximately 50
2to 100 cells/mm3 per year until a steady state level is reached. The absolute number CD4
cell count may  fluctuate in individuals or may be influenced by factors that may affect the
total WBC count and lymphocyte percentages (7, 9).
In resource-limited countries 18.8% of HIV patients on second line ART met WHO failure
criteria (10). In southeastern Ethiopia the incidence rate of treatment failure  among adults
was found 9.38 per 1000 person years(11). In northwest Ethiopia the incidence rate of
treatment failure among Adults in second line ART was found 61.7/1000 person years(12).
Also in the above area the incidence rate of immunological failure were found 8 per 100
person-years(13).
Treatment failure is associated with both patient and regimen related factors, some of them
are incomplete medication adherence and missed clinic appointments, drug adverse effects,
prescription errors, co morbidities and lower pretreatment (7). Adherence to ART is central
to therapeutic success. Strict adherence in ART is a key variable to sustained HIV
suppression, reduced risk of drug resistance, improved overall health, quality of life, and
survival(2).
Evaluation of treatment failure should include an assessment of adherence, drug-drug or
drug-food interactions, drug tolerability, HIV RNA and CD4 T lymphocyte (CD4) cell count
trends over time, treatment history, and prior and current drug-resistance testing results.
Some of the strategies to improve adherence to ART are use a multidisciplinary team
approach, identify facilitators, potential barriers to adherence, management skills before
starting ART medication, assess adherence at every clinic visit and use positive
reinforcement to foster adherence success(2).
In resource-limited countries, second-line treatment is often the last therapeutic option
available for patients, there for maximizing the duration of second-line regimens is important
(10). However, there remains to explore more on predictors of time to treatment failure, In
addition to HIV CD4 cell counts are influenced by other factors and due to measurement
error in the repeated measurement and informative dropout, separate analysis does not fully
exploit the association between the repeated measurement process and the hazard for
3survival. The study was aimed to assess the long term outcome of ART regarding time to
treatment failure and the rate of change in CD4 cell counts on second line antiretroviral
therapy.
41.2 Literature review
1.2.1 Incidence rate of treatment failure and change in CD4 cell count
Virologic failure is the inability to achieve or maintain suppression of viral replication to HIV
RNA level <200 copies/ml (2). In South Africa (14) 13.4% of HIV positive patients in second
line ART confirmed Virologic failure without resistance. A study (10) aiming on treatment
failure and mortality factors in patients receiving second-Line HIV therapy in resource-limited
countries, shows among HIV positive patients in second line ART 18.8% met treatment
failure with a median time of 11.9 months following the start of second-line therapy.
A study done in Brazil (15) found the mean increase of CD4 cell count was 1.529
cells/mm3 per month. Also a study in Mildmay Uganda (16) indicates the CD4 cell counts
level was increased in the first 5 to 9 months from ART initiation and then showed stable
evolution. Furthermore a study in Gondar Ethiopia (17) on Predictors of CD4 Count
Changes after Initiation of ART indicates the average rate of CD4 cell count change was
found 1.06 per week.
Studies in southern Ethiopia shows the incidence rate of treatment failure among adult HIV
patients initiated ART was found 9.38 per 1000 person years (11, 18). A study done (12) in
northwest Ethiopia on second-line antiretroviral therapy among adults shows the overall
incidence of treatment failure was 61.7 per 1000 person years. A Retrospective Follow up
study in northwest Ethiopia (13) on rate of immunological failure and its predictors among
patients on highly active antiretroviral therapy shows, the incidence of treatment failure were
8 per 100 patient-years.
1.2.2 Associated factors of time to treatment failure and change of CD4 cell count
A study in south eastern Ethiopia(11) indicates being  male, lower baseline CD4 cell count ,
poor drug adherence ,older age and TB co -infected were more likely to experience
treatment failure compared to their counter parts. Further more on this area, ART clients sex
male, lower education and TB co -infected was significantly associated with higher odds of
mortality comparing with female, higher educational status and without TB co -infected
respectively(18).
Also Patient characteristics like a negative change in weight during the study period, a CD4
count <100 cells/mm3 at switch and patients categorized as WHO clinical stage IV at switch
5was  found a significant predictors for second line treatment failure among adults northwest
Ethiopia (12). A retrospective follow up study in Debere Markos Hospital (13) shows being
unemployed, unable to work, lower CD4 cell counts, less body weight are associated with
the risk of immunological failure. In the study done (19) male sex, poor baseline
performance scale, low baseline bodyweight, and worse baseline WHO clinical were a
significant associated factor of mortality among adult HIV-infected patients on ART,
surprisingly baseline CD4 count was not significantly associated with mortality, also this
study shows mortality for those taking second-line therapy was lower in women and in rural
than in Male and urban sites respectively. Patients who met criteria for treatment failure of
any type, and those diagnosed with immune virological failure were at increased risk of
death compared with other patients but Length of time on first-line therapy before second-
line therapy start was unrelated to mortality. Among patients in Africa and Asia, treatment
failure was associated with low CD4 cell counts at second-line therapy start, use of
suboptimal second-line regimens, and poor adherence (10). On the other hand (4) low CD4
cell counts were associated with early mortality. From a study in South Africa (20) on
Second-Line Antiretroviral Therapy indicates, patients had high rates of immunologic and
Virologic success and low rates of mortality over the first year on second-line treatment.
A study done in Mildmay Uganda (16) shows gender, baseline age, and baseline WHO
clinical stages were significant predictors the change in CD4 cell count.
A research done in university of Gondar (17) on predictors of CD4 count changes after
initiation of antiretroviral treatment shows  age at the  starting ART, educational status,
marital status, WHO clinical staging, baseline hemoglobin level, baseline CD4 count, ART
adherence status, functional status, and recent follow up CD4 are significant predictors of
CD4 count change. A research done in northwest Ethiopia (21) sex difference was not
obtained on average CD4 cell count increment and in the first six months both sexes had
the highest average rates of increment of CD4 cell count. A study (22) shows patients with
baseline CD4 cell counts of 200 cells/μ had greater rates of immunological response
compared to those with higher baseline CD4 cell counts ,and the highest CD4 cell counts
were achieved when ART was started at a baseline CD4 cell count >350 cells/μL. An
6increased risk of immunological non-response was significantly observed among male
patients.
1.2.3 Review of joint modeling for longitudinal and survival data
Depending on the research objective three situations are applicable in joint modeling
approach. The main focus may be modeling survival data, this situation arise in survival
model, when time-dependent covariates measured with error or missing at failure times.
Modeling the longitudinal covariate processes is only used to address measurement errors
or missing data. The second main focus is modeling longitudinal data, in this situation; a
survival model is only used to address the informative dropouts. The third main focus is on
modeling both the longitudinal data and the survival data, with a goal of understanding the
association between the two processes(23).
In joint modeling approach longitudinal process and the risk for time-to-event depend jointly
on shared, underlying random effects(24). A research (25) aims to assess the Impact of
CD4 cell count on risk of loss to follow up in HIV/AIDS patients on antiretroviral therapy
indicates joint models is appropriate when the longitudinal variable  associated with time to
event. Also this study generalizes joint model should be preferred over separate models for
longitudinal and survival data analysis. Also from a study (26) on joint modeling of
longitudinal CD4 counts and survival of HIV-infected patients initiated on antiretroviral
therapy in sub-Saharan Africa, indicates joint modeling with a latent structure approach
provides a powerful tool to estimate simultaneously the effect of a longitudinal marker and
the risk on survival.
Furthermore treatment related variables like treatment modification, second line regimen,
INH taking, CPT taking were included in this study to know the effect on change of CD4 cell
count and time to treatment failure.
Over all in the literature, treatment failure and CD4 cell count associated with socio
demographic, clinical and treatment related factors.
7Figure 1: Conceptual frame work
Conceptual framework of change in CD4 count and time to treatment failure after adaption
of literature (11, 12, 18, 27)
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81.3 Justification of the study
Monitoring HIV patients in resource limiting setting on second line ART is crucial to ensure
successful treatment, identify adherence problems and determine whether ART regimens
should be switched in case of treatment failure. In second line ART only few studies were
conducted in the Globe and in Ethiopia on predictors of time to treatment failure and on the
rate of CD4 cell count change.
However, there remains to explore more on predictors of time to treatment failure and on the
rate of CD4 cell count change. Also due to measurement error in the repeated measurement
and informative dropout, separate analysis does not fully exploit the association between the
repeated measurement process and the hazard for survival.
Thus the motivation of this study was to analyze jointly repeated measurements of
biomarkers (CD4 cell count) and time to treatment failure with their associated factors from
second line ART among Adults in Amhara region.
92. Objective
2.1 General objective
The general objective of this study was to assess the change in CD4 cell count and time to
treatment failure as well as their risk factors from second line ART among adults in Amhara
region
2.2 Specific objective
To determine the incidence rate of treatment failure from second line ART among Adults in
Amhara Region
To determine the rate of change in CD4 cell count from second line ART among Adults in
Amhara Region
To identify associated factors on CD4 cell count change from second line ART among
Adults in Amhara Region
To identify risk factors of time to treatment failure from second line ART among Adults in
Amhara Region
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3.  Methods and materials
3.1 Study design and period
An Institutional based retrospective follow up study was conducted among Adults aged 15
and above who started second line ART between 2008 and 2016 in eight selected hospitals
of Amhara region.
3.2 study setting
A study was conducted in eight Amhara region zonal Hospitals, which are University of
Gondar Hospital, FelegeHiwot referral Hospital, Debre-Markos Hospital, Dessee referral
Hospital, Debre -Tabor Hospital, Woldiya Hospital, Finoteselam Hospital and Debrebirhan
Hospital. Gondar University Hospital is a teaching referral hospital in northwest Ethiopia, the
ART Clinic provides ART care and HIV counseling and testing. The Hospital provides
different inpatient and outpatient services to the population in the surrounding area of
Gondar town and the nearby zones. Debre Tabor Hospital provides health services to more
than 2.3 million people for inpatients and outpatients. ART service for both experienced and
naive HIV-1 patients has been given in the hospital since 2006. Felege Hiwot Referral
Hospital located in the capital city of the Amhara Region, Bahirdar. The ART clinic in the
hospital gives Voluntary Counseling and testing services in addition to ART care.
Debre- Markos and Finote-Selam Hospitals located in neighboring Zones of eastern Gojam
and West Gojam respectively. The two Hospitals provide voluntary counseling and testing
(VCT), prevention of mother to child transmission (PMTCT), antiretroviral therapy (ART) and
treatment of opportunistic infection services. Debrebirhan referral hospital is located in the
North Shoa Zone of Amhara Regional State. The referral Hospital provides care and
treatment for HIV/AIDS patients from parts of Oromo and Afar regions. Dessie Referral
Hospital is the biggest service delivery referral hospital including ART in South Wollo Zone,
Northeast Ethiopia. Woldiya Hospital is located north east of Addis Ababa, capital city of
Ethiopia and one of the Hospitals with large number of HIV patient flow. In the hospital,
voluntary counseling and testing (VCT), ART and treatment of opportunistic infection (TOI)
services are available.
11
3.3 Source and Study population
The source and study population included all adults aged 15 and above years old who
registered and started second line ART in Amhara region between February 2008 and 2016
3.4 Inclusion criteria
All adults aged 15 and above who have follow-up of at least six months on second line ART.
3.5 Exclusion criteria
HIV positive individuals with incomplete base line information like CD4 cell count and WHO
clinical stage was excluded from the study
3.6 sample size determination
3.6.1 Sample size determination for survival out come
Sample size was determined by using sample size determination formula for survival
analysis with assumptions of 95% level of confidence, and 80% power. The minimum
adequate sample size is given by = ( α β)
Where " ⁄ "the level of confidence is, " " is the probability of rejecting false hypothesis."b "Is the square of log hazard ratio, "p " and "p " are the proportion of group one and
group two respectively and “ " is the proportion of patients developed an event which are
computed from previous study(13).Furthermore three factors are considered for sample size
determination. Procedures are given in the table below.
Table 1: Sample size determination for survival out come by considering three key factors
Factor HR (b2=log2(HR)) P1 P2 Sample size
CD4 count(base line) 2.18 (0.114) 0.589 0.411 1306
WHO stage(baseline) 4.11 (0.376) 0.627 0.373 713
Weight change 3.53 (0.300) 0.448 0.552 490
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3.6.2 Sample size determination for longitudinal outcome
Assumptions:
All subjects measured at m = 10 time points (no drop-out) Constant within-subject
correlation = 0.5, =1, we want 90% power to detect a difference “d” of 0.25 at the two-
sided 0.05 level.
=
( ( ) )( )
= ( . )( . . )( . ) = 369.52 ≈ 370
Considering the above two methods, the minimum adequate sample sizes for both survival
(time to treatment failure) and longitudinal outcome (change in CD4 cell count) were 370
and 1306 respectively. But the total numbers of patients on second line ART who fulfill the
inclusion criteria in the eight selected Hospitals were 1233 and to increase the power of the
study all were included.
3.7 Study variables
3.7.1 Dependent variables
The dependant variables in this study were Change of CD4 cell count and time to treatment
failure
3.7.2 Independent variable
Socio–demographic characteristics: baseline Age, gender, baseline weight, baseline
educational status, baseline functional status
Clinical characteristics: TB status, WHO clinical stage CD4 cell count at switch
Treatment related characteristics: ART Adherence, regimen modification, drug type
(second line drug regimens), taking INH, taking CPT
3.8 Operational definitions
Treatment failure: A client experience one of Clinical failure, Immunological failure, or both.
We use WHO consolidated guide line for the use of antiretroviral drugs for treating and
preventing HIV infection second edition, 2016
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Time to treatment failure: is the time from switching to second line ART up to treatment
failure.
Censored: Those HIV positive patients on second line ART without experiencing treatment
failure in the follow up period
Adults: Those HIV positive patients on second line ART with age 15 years and above
Functional Status
Working: Able to perform usual work in or out of the house.
Ambulatory: Able to perform activities of daily living.
Bedridden: Not able to perform activities of daily living
Regimen modified: those modified the regimen at least once in the follow up period
Adherence: Good adherence is >95%, fair adherence 85%-95% and poor Adherence <85%
of drug intake over the duration of the follow up.
3.9 Data collection tools and procedures
Standardized check list was used for data collection. All Adult clients’ information recorded
from their chart by nurses who were taking training on ART. To make easy the process
variables were recorded as baseline variables and follow-up variables.
3.10 Data quality control
The quality of data was insured by training data collector, closed supervision and reviewing
the collected data before leaving the study area, checking for any inconsistencies, coding
error, out of range, completeness, accuracy, clarity , missing values and appropriate
corrections was made by the principal investigator and supervisors .
3.11 Data analysis
3.11.1 Joint Modeling of longitudinal and survival data
The rate of an event is not only different from patient to patient but also dynamically
changes in time for the same patient. The extended Cox model is only appropriate for
exogenous time-dependent covariates and therefore cannot handle longitudinal biomarkers
(28).The joint likelihood approach arises to avoid the potential bias caused by the time
dependent Cox model and two-stage approach. This is done by taking into account the
association between the survival and the longitudinal processes by simultaneously
determining the parameter estimates for both processes (24). Depending on the research
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objective three situations are applicable in joint modeling approach. The main focus for this
study is modeling survival data with modeling longitudinal data being secondary. The joint
model consists of two linked sub models, known as the longitudinal sub model, and the
survival sub model.
We let ∗ denote the true event time for the ith subject, the observed event time, defined
as the minimum of the potential censoring time and ∗ , and by = ( ∗ ≤ ) the
event indicator (treatment failure). For the endogenous time-dependent variable (CD4 cell
count) also we let ( ) denote its observed value at time point t for the ith subject. We
should note that we do not actually observe ( ) for any time t, but rather only at the very
specific occasions at which measurements were taken. Thus, the observed CD4 cell
count consist of the measurements = { ( ), = 1, . . . , }.
The mathematical formulations for Joint model can be defined by the two equations= ( )+ , where ( ) = + ………………………………………… (3)( | ( ), ) = ( + ( ))…………………………………………… .(4)
Where “α” quantifies the effect of the underlying longitudinal CD4 cell count to the risk for
treatment failure, moreover, it is assumed that the risk for treatment failure dependent
dropout is associated with the true and unobserved value of the longitudinal CD4 cell count.
3.11.1.1 Longitudinal Sub model
In order to reconstruct the complete true history Mi(t) to each subject, linear mixed model is
needed. Let denotes the log CD4 cell count of subject , = 1, . . . , at time , =1, . . . , . the linear mixed model has the form= + b + ,b ∼ (0, ),∼ (0, I ),
Where and are known design matrices, for the fixed-effects and the random-effects
respectively, and denotes the dimensional identity matrix.  The random effects are
assumed to be normally distributed with mean zero and variance-covariance matrix D, and
are assumed independent of the error terms , . . , ( , ) = 0.
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β Denotes the change in the average log CD4 cell count when the corresponding covariate
is increased by one unit, while all other predictors are held constant, similarly the random
effects are interpreted in terms of how a subset of the regression parameters for theℎ subject deviates from those in the population.
The main reasons for the use of mixed models in the joint modeling framework is that it is
not only possible to estimate parameters that describe how the mean response changes in
the population of interest, but it also possible to predict how individual response trajectories
change over time. In addition, mixed models can accommodate any degree of imbalance in
the data (28)
3.11.1.2 Survival Sub model
The objective of survival sub model is to associate the true, unobserved value of the
longitudinal outcome at time t, ( ) with time to treatment failure of individuals. The relative
risk model was given by equation “4”.
Where ( ) denotes the true, unobserved longitudinal process up to time point t, "λ0”
denotes the baseline risk function, and " " is a vector of baseline covariates, with a
corresponding vector of regression coefficients " ". “ ” quantifies the effect of the
underlying longitudinal CD4 cell count to the risk for treatment failure. The interpretation
of " " and “ ” is in terms of hazard ratio. In particular, (" ") denotes the ratio of
hazards for one unit change in " " at any time t, whereas " ( )" denotes the relative
increase in the risk for an event at time t that results from one unit increase in " ( )" at the
same time point and keeping other factors constant.
Several approaches have been proposed in the literature to flexibly model the baseline risk
function. Two options that often work quite satisfactorily in practice are the piecewise-
constant with six knots placed at equally spaced percentiles of the observed event times
and regression splines approaches with five internal knots placed at equally spaced
percentiles of the observed event times (28)
3.11.1.3 Parameterization of joint model
The standard joint model, assumed that the risk for an event at a particular time point t
depends on the true level of the longitudinal marker at the same time point, that is the
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strength of the association between the current level of the marker and the risk is captured
by the parameter “α”.
The general formulation of the association structure between the longitudinal marker and the
risk for an event is:( | ( ), ) = ( + { – , , ; })
Where, (·) is a function of the true level of the marker (·), of the random effects and
extra covariates 2. Under this general formulation α can potentially denote a vector of
association parameters rather than a simple scalar.
3.11.1.3.1 Interaction effects
The standard parameterization presented in equation “4” assumes that the effect of the true
level of the CD4 cell count is the same in all subgroups of the target population. This is
evidently a strong assumption that may not be true when the marker behaves differently for
different subgroups of subjects. To include the interaction terms of the marker (CD4 cell
count) with baseline covariates of interest is:ℎ ( ) = ℎ0( ) [ + { × ( )}]
Where, is used to accommodate the direct effects of baseline covariate to the risk for
treatment failure and contains interaction terms that expand the association of ( ) in
different subgroups.
3.11.1.3.2 Lagged Effects
Sometimes the assumption that the current value of the time dependent variables affects the
current risk for an event may lead to wrong conclusions. One approach to tackle such
situations is to use time-lagged covariates
The formulation of the relative risk model is:ℎ ( ) = ℎ0( ) [ + {max ( − , 0)}] , which postulates that the risk at time t
depends on the true value CD4 cell count at time t−c, where c specifies the time lag of
interest.
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3.11.1.4 Estimation of Joint Models
The likelihood method for joint models is based on the maximization of the log-likelihood of
the joint distribution of the time-to-event and longitudinal data. Estimates are derived as the
modes of the log-likelihood function corresponding to the joint distribution of the observed
outcomes. To define this joint distribution we assume that the vector of time dependent
random effects" ” underlies both the longitudinal and survival processes.
Assume bi, account for the association between the longitudinal and the event process,
also, the longitudinal process and the survival process is conditionally independent given bi.
We have that( . , | ; )= ( . | ; ) ( | ; )( | ; )=∏ ( ( )| ; )= ( , , ) “ " Denoting the parameters for the event time outcome, " " the
parameters for the longitudinal outcomes and " " the unique parameters of the random-
effects covariance matrix, In addition, we assume that given the observed history, the
censoring mechanism and the visiting process are independent of the true event times and
future longitudinal measurements.
The log-likelihood contribution for the ith subject can be formulated as follows( . , ; ) = ( . , , ; )
= ∫ ( . , | ; , )[∏ ( ( )| ; )] ( , ) ………………...... (5)
With the conditional density for the survival part ( . , | ; , ) taking the form( . , | ; , ) = ℎ ( | ( ); , ) ( | ( ); , )……………… (6)
= [ ( ) ( + T(i)) ] × exp (−∫ ( ) ( + ( ))
The joint density for the longitudinal responses together with the random effects is given by( | ; ) ( , ) = ∏ ( ( )| ; ) ( ; ) ………………………. …(7)
Maximization of the log-likelihood function can be achieved using standard algorithms, such
as the Expectation-Maximization, Newton-Raphson algorithm or any of its variants.
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3.11.1.5 Model comparison
Different mean structures for longitudinal sub model and different baseline risk function for
survival sub model were compared using, Akaike Information Criterion (AIC) and BIC for
non-nested models, and Log-Likelihood Ratio test for nested models.
AIC is widely used criterion which is defined as AIC = l(b) − 2p where, l(b) is the log
likelihood of the typical model and p is the number of parameters in the model. Also Log-
Likelihood Ratio test is asymptotically chi-square distributed and given asXL = −2 (log likelihood (saturated model) − log likelihood (reduced model)
Furthermore the Bayesian information criterion (BIC; Schwarz, 1978) used for non- nested
models and it demands the number of parameters in the distribution (p), and the total
number of observations (n).
For each candidate distribution we have BIC = l(b) − logn
3.11.1.6 Joint Model Diagnostics
Before performing inference it is important to determine whether all the necessary
assumptions are valid or not. Diagnostic plots to check the fit of mixed models and relative
risk models were used, but in joint modeling framework; it is assumed that the occurrence of
events is related with the underlying evolution of the subject specific longitudinal profiles,
which corresponds to a non-random dropout mechanism. The calculated residuals do not
constitute a random sample of the target population, so the residuals are not expected to
exhibit standard properties, such as zero mean and independence. To overcome this
problem(28) proposed a new method for calculating residuals and producing diagnostic
plots in joint models, based on creating random versions of the completed data set by
multiple imputation of the missing longitudinal responses under the fitted joint model.
In linear mixed-effects model, two types of residuals are often used, namely the subject-
specific and the marginal residuals. The subject-specific residuals aim to validate the
assumptions of the hierarchical version of the model, i.e.= + +~ (0, ) ~ 0,
= { − − } ………………………….................. ……………………………... (8)
With corresponding standardized version
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= { − − }/ ……………………………………………………………………..(9)
Where,”β” and" ” denote the MLEs and “ ” the empirical Bayes estimates for the random
effects. These residuals predict the conditional errors “εi”, and can be used for checking the
homoscedasticity and normality assumptions.
On the other hand, the marginal residuals focus on the marginal model for" ", that is:
= + ∗∗ ~ 0, +
And defined as ∗= − ………………………………………………………… (10)
With corresponding standard version
∗ = / ( − )………………………………………………………………… (11)= + , denotes the estimated marginal covariance matrix of " ”
These marginal residuals ∗ predict the marginal errors − = + , and can be used
to investigate misspecification of the mean structure as well as to validate the
assumptions for the within-subjects covariance structure . Both types of residuals can be
used to check the assumptions of the longitudinal part of a joint model as well.
A standard type of residuals for the relative risk sub model of the joint model is the
martingale residuals, based on the counting process notation of time-to-event data, and in
particular on the subject-specific counting process martingale, which is defined for the ith
subject as
( ) = ( ) − ( )ℎ ( | ( ); )
= ( ) − ∫ ( )ℎ ( )exp ( + ( )) ……………………………… (12)
Where ( ) is the counting process denoting the number of events for subject i by time t,( ) is the left continuous at risk process with ( )= 1 if subject i is at risk at time t, and
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( )= 0 otherwise, ( ) = + , and ℎ denotes the estimated baseline risk function. In
plain terms, the residual ( ) can be viewed as the difference between the observed number
of events for the ith subject by time t, and the expected number of events by the same time
based on the fitted model. An alternative type of residuals for survival models, related to the
martingale residuals, is the Cox-Snell residuals (Cox and Snell, 1968). For each subject,
these are calculated as the value of the estimated cumulative risk function evaluated at the
observed event time .
3.12 Ethical consideration
Ethical clearance was obtained from the Ethical Review Board of the University of Gondar.
A letter of permission was collected from the respective ART clinics of each hospital.
Moreover, the confidentiality of information obtained was guaranteed by using code
numbers rather than personal identifiers and by keeping the checklist locked.
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4. Results
4.1 Baseline socio-demography, clinical and treatment related characteristics of the
study participants
A total of 1233 HIV positive patients receiving second line ART on the selected Hospitals of
Amhara region were eligible in the study. Two hundred twenty two(18%) of a total HIV
patients were excluded from the study due to CD4 cell count and WHO clinical stage should
measured two and above in order to define the immunological and clinical failure. The
average age of study participants at switch were 33.22 years with standard deviation of 8.86
years. The mean CD4 cell count and weight at switch of study participants were 254.63
cell/mm3 and 52.14 kg respectively (table2).
Table 2: Descriptive Statistics of Continuous Covariates at switch
Variables Mean Std
Dev.
minimum maximum
Age at switch 33.22 8.86 15 77
CD4 cell count
at switch
254.63 176.00 15 1477
Weight at
switch
52.14 10.35 23 92
Descriptive statistics for categorical characteristics as presented in “table5” shows nearly
half of 498 (49.16%) study subjects were female. Four hundred thirty five (43%),
353(34.9%), 277(27.4%) and 78(7.72%) of patients were modified drug regimens, had poor
ART adherence, taking INH and had opportunistic infection respectively. Also four hundred
sixty eight (46.29%), 89(8.8%), 371(36.69%) and 83(8.21%) of study participants were
under WHO clinical stage I, II, III and IV respectively. Furthermore eight hundred fifty six
(84.67%), 137(13.55%) and 18(1.78%) of HIV positive patients had functional status of
working, ambulatory and bedridden respectively.
4.2 Exploratory Data Analysis
Exploring the data prior to fitting the model could be used as a guide for the modeling
framework. The two outcomes were explored separately to obtained appropriate sub models
in joint modeling frame work.
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4.2.1 Exploring change of CD4 cell count
4.2.1.1 Normality Assumption checking
The CD4 cell counts data exhibited high variability and it was heavily skewed to the right.
To get rid of the skewness in CD4 cell count log transformation was applied and the analysis
was carried on with the transformed outcome. The normality of the data was checked by Q-
Q plot. Nearly no deviations from the reference line indicate that the data was approximately
normally distributed after transforming in natural logarisim (see annex1, Figure6).
4.2.1.2 Exploring the mean structure
In the follow up period the average rate of CD4 cell count change was found 1.13 cell/mm3
with mean±SD of (-0.03, 2.29) per six months.  From general over view the mean of log
CD4 cell count is increasing through time but the standard deviation is decreasing through
time.
Table 3:mean and standard deviation of log CD4 cell count at each visit from second line
ART among adults in Amhara region (February, 2008 – 2016)
Visit Baseline(0) 1 2 3 4 5 6 7 8 9 10 11 12
Mean 4.74 5.31 5.5 5.65 5.69 5.74 5.82 5.88 5.89 5.97 6.02 6.15 6.21
StDev 0.941 0.71 0.72 0.69 0.69 6.39 0.61 0.63 0.67 0.64 0.38 0.35 0.33
Since the nature of the data for this study was unbalanced , neither the same number of
measurements on each subject nor that these measurements be taken at the same set of
occasions, smoothed mean profile was plotted to explore the mean structure. The individual
trajectory for the first one hundred study participants (for better visualize) and the smoothed
mean profile (figure 2) , which shows patients had considerably different CD4 cell counts at
the start of ART and this may suggest the need for subject specific intercepts during mixed
effect modeling. Also, patients evolved differently, some showed faster growth and some
others showed a declining CD4 counts, hence it is statistically plausible to suggest the
requirement of subject specific slopes that could capture the individual level evolutions
under mixed effect modeling framework. Furthermore the mean profile reveals the mean
structure of log CD4 cell count and time seems linearly related.
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Figure 2:Trajectory of log (CD4) cell count (left side ) for the first 100 study subjects and
smoothed mean profile (right side) from second line ART among adults in Amhara region
(February, 2008 – 2016)
Smoothed mean structures of log CD4 cell count stratified by factor variables (see figure 3
and annex1) reveals HIV positive patients starting second line ART under WHO stage4,
second line regimen AZT-3TC-LPV/r, being male, not modified regimen and lower ART
adherence status had lower mean profile relatively with their counter parts.
In addition to the individual profile plot the need of random effects were formally tested. In
“table4” below shows both random intercept and slope were needed in linear mixed model
frame work.
Table 4: Testing the need for random effects
Random effect LR test p-value
1585.84 <0.0001∗ 391 <0.0001
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Figure 3: Smoothed mean profile for log (CD4) cell count by factor variables  from second
line ART among adults in Amhara region (February, 2008 – 2016). (A) Smoothed mean
profile for log (CD4) cell count by Regimen modification,(B) Smoothed mean profile for log
(CD4) cell count by gender,(C) Smoothed mean profile for log (CD4) cell count by WHO
clinical stage,(D) Smoothed mean profile for log (CD4) cell count by INH given
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4.2.1.3 Exploring the variance covariance structure
The correlation matrix (see annex1) reveals there were anon-ignorable correlations of log
CD4 cell count between subsequent measurements. Regarding the covariance matrix of the
random effects, joint model assumes it to be unstructured and estimates all of its free
parameters(28)
4.2.2 Exploring treatment failure
The median failure time of adult HIV positive patients in this study was found 12.93 with
inters quartile range (7.6, 23.5) months. In the first year 114(44.88%) of the study
participants were experience treatment failure which is high comparing to other years (see
annex1).From male HIV patients 50.74% of them were experiencing treatment failure with
median failure time of 14.13 months. Also from HIV patients who modified regimen at least
once in the follow up period 33.46% of them were experiencing treatment failure with a
median failure time of 12.93 months.
From those HIV patients under second line regimen ABC-ddI-LPV/r, TDF-3TC-LPV/r, AZT-
3TC-LPV/r 13.78%, 37%, 14.57% of them experience treatment failure with median failure
time of 16.1, 13.85, 13.23 months respectively. Also from those HIV patients who had poor
ART adherence, faire ART adherence and good ART adherence 31.16%, 21.94% and
21.86% of them experience the treatment failure with median failure time of 13.92,12.16
,13.53 months respectively. Furthermore those taking INH HIV patients 20.07% of them
experience treatment failure with median failure time of 15.66 months (table5).
In the follow up period the study subjects contributed a total of 2569.68 person-years and
the incidence rate of treatment failure was 9.88 (95%CI 0.087-0.11) per 100 person years.
(See table6)
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Table 5: Median failure time and frequency of socio demographic, treatment related and
clinical characteristics from second line ART among adults in Amhara region (February,
2008 – 2016)
Variable Frequency (%) Treatment failure Median failure
time(months)
Event Censored
Gender
Female
male
498(49.26%)
513(50.74%)
118
136
380
377
14.13
12.78
Regimen modification
No
yes
576(56.97%)
435(43.03%)
169
85
407
350
13.23
12.93
ART adherence
Poor
Fair
good
353(34.92%)
196(19.39)
462(45.69%)
110
43
101
243
153
361
13.92
12.16
13.53
WHO clinical stage
I
II
III
IV
468(46.29%)
89(8.8%)
371(36.69%)
83(8.21%)
114
20
84
36
354
69
287
47
11.95
14.13
13.09
18.52
INH given
No
Yes
734(72.6%)
277(27.39%)
203
51
531
226
13.16
15.66
CPT given
No
Yes
280(27.69%)
731(72.30%)
61
193
219
538
14.96
13.23
Functional status at switch
Working
Ambulatory
bedridden
856(84.67%)
137(13.55%)
18(1.78%)
206
40
8
650
97
10
13.66
11.93
13.98
OI
No
yes
933(92.28%)
78(7.72%)
236
18
697
60
13.25
10.72
Second line regimen
ABC-ddI-LPV/r
TDF-3TC-LPV/r
AZT-3TC-LPV/r
Others*
189(18.69%)
351(34.72%)
106(10.48%)
365(36.10%)
35
94
37
88
154
257
69
277
16.1
13.85
13.23
11.85
*= (ABC-ddI-NFV, AZT-3TC-ATV/r, TDF-3TC-ATV/r, ABC-3TC-LPV/r, and ABC-3TC-ATV/r)
The Kaplan – Meier survival estimator curve of treatment failure (see figure 4) reveals the
median survival time of HIV positive patients from second line ART were 92 months.
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The median survival time for those HIV positive patients who have poor adherence and
good adherence were 89.2 and 92.5 months respectively.
Table 6: Incidence rate in person years from second line ART among adults in Amhara
region (February, 2008 – 2016)
Person-time(in
years)
failures Rate [95% Conf.
Interval]
2569.68 254 0.0988 0.087     0.11
Figure 4: Kaplan-Meier survival estimator curve for treatment failure(left side)  and Kaplan-
Meier survival estimator curve for treatment failure stratified by ART Adherence (right side)
from second line ART among adults in Amhara region (February, 2008 – 2016)
The Kaplan – Meier survival estimator curve of treatment failure for factor variables are
presented in (Figure 5 and annex1, figure9). The median survival time of female and male
HIV positive patients were 92.5 and 92 months respectively, Also who started second line
regimen under ABC-ddI-LPV/r, TDF-3TC-LPV/r, AZT-3TC-LPV/r had a median survival time
of 94.3 ,89.2 and 48.9 months respectively. The median survival time for those HIV positive
patients who were not change the regimen and not take INH were 89.2 and 92 months,
Furthermore HIV positive patients under WHO clinical stage III and stage IV at switch have
the median survival time of 92 and 65.2 months respectively.
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Figure 5: Kaplan-Meier survival curve of treatment failure by factor variable from second
line ART among adults in Amhara region (February, 2008 – 2016) , (A) Kaplan-Meier
survival curve by regimen modification, (B) Kaplan-Meier survival curve by WHO clinical
stage,(C) Kaplan-Meier survival curve  INH given,(D) Kaplan-Meier survival curve by
gender.
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4.2.2.1 Proportional hazard assumption checking
The proportional hazards assumption, which asserts that the hazard ratios are constant
overtime, is vital to the interpretation and use of a fitted proportional hazards model. That
means the risk of treatment failure must be the same no matter how long subjects have
been followed.
The proportional hazard assumption was checked by fitting an extended Cox model
interaction with time. Since none of variable show significant at 5% level of significance, the
proportional hazard assumption is fulfilled (see table 7).
Table 7: Proportional Hazard assumption checking from second line ART among adults in
Amhara region (February, 2008 – 2016)
Effects HR 95% CI(HR)
Gender
Female
male
1
1.002 (.986    1.0189)
ART adherence
Poor
Fair
good
1
1.003
.990
(.981   1.026)
(.974   1.007)
CD4 at switch
>100cells/mm3
≤100 cells/mm3
1
.994 (.978    1.010)
Regimen modification
No
Yes
1
.999 (.981   1.017)
Second line regimen
ABC-ddI-LPV/r
TDF-3TC-LPV/r
AZT-3TC-LPV/r
Others*
1
1.004
1.030
.991
(.979   1.028)
( .996    1.066)
(.968   1.014)
Taking INH
No
yes
1
.998 (.981      1.015)
*= (ABC-ddI-NFV, AZT-3TC-ATV/r, TDF-3TC-ATV/r, ABC-3TC-LPV/r, and ABC-3TC-ATV/r)
4.3 Joint modeling of change in CD4 cell count and time to treatment failure
Linear mixed-effects model and relative risk model with spline-PH-GH baseline risk function
was fitted jointly. The time variable that used in the linear mixed model was required in the
internal competition of the true unobserved CD4 cell count measurements.
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4.3.1 Comparing joint models
Different specification of the baseline risk function for survival sub model is presented in the
“table8” below. Using model selection criterion the relative risk model with a spline
approximation of the log baseline risk function was found better.
Table 8: model comparison by specification the baseline risk function from second line ART
among adults in Amhara region (February, 2008 – 2016)
Baseline risk
function
AIC BIC Log likelihood
piecewise-PH-GH 11812.11 11994.1 -5869.056
Weibull-PH-GH 11776.79 11934.19 -5856.394
Weibull-AFT-GH 11776.57 11933.97 -5856.287
spline-PH-GH 11769.08 11960.9 -5845.538
It is assumed that the risk for treatment failure at a particular time point t depends on the
true level of the CD4 cell count at the same time point, but it is not realistic to expect that
this parameterization will always be the most appropriate in expressing the correct
relationship between the change in CD4 cell count and time to treatment failure. To
overcome these, Parameterizations by current value, interaction effects (for gender and
ART adherence) and lagged effects (by six month) were compared at spline-PH-GH
specifications of the baseline risk function (table 9). Even though parameterization by lagged
effects shows the strong association of CD4 cell count and time to treatment failure, in over
all model comparison current value parameterization was better than the other.
Table 9: comparing different parameterization at spline-PH-GH specifications of the
baseline risk function from second line ART among adults in Amhara region (February,
2008 – 2016)
Parameterization AIC BIC Log likelihood Association
value(α)
Current value 11769.08 11960.9 -5845.538 -1.756
Interaction effects 11774.67 11971.42 -5847.336 -1.606
Lagged effects
(for six months)
11809.73 12001.56 -5865.863 -2.159
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4.3.2 Joint results of change in CD4 cell count and time to treatment failure
After different proposed joint models compared, the final joint model was fitted by current
value parameterization with spline-PH-GH specifications of the baseline risk function.   We
observe strong evidence that the current unobserved true level of log CD4 cell count is
associated with the risk of treatment failure (see table 11). A unit increase in the current
value of log CD4 cell count resulting 83% of reducing the risk of treatment failure taking the
assumption that the effect of the true level CD4 cell count is the same in all subgroups of the
target population.
The joint modeling gives associated factors for both changes in log CD4 count and time to
treatment failure (see both table1 and table2). Result shows, ART adherence, base line CD4
cell count and modified regimens were found significant predictors of change in log CD4 cell
count, where as baseline CD4 cell count, second line regimen and taking INH also were
significant predictors of time to treatment failure.
Being male, modified regimen, having good ART adherence, and baseline CD4 cell count
(≤100 cell/mm3 ), the average log CD4 cell count changes by -0.051, 0.105, 0.079 and -
0.966 relatively with their counter parts while all other predictors held constant. The random
effect of linear mixed model  show us the log CD4 cell count of study subjects deviate on
average by 0.365 from the population at the start of second line ART, and with time  the log
CD4 cell count of study subjects deviate on average by 0.025 from the population.
Baseline CD4 cell count (≤100 cell/ mm 3), being male, second line regimen under TDF-
3TC-LPV/r   and AZT-3TC-LPV/r, not taking INH increases the risk of treatment failure
comparing with their counter parts. The overall effect of lower CD4 cell count (≤100 cell/ mm
3) at initiation of second line ART treatment is (-1.756*-0.966+1.029) =2.725, which is the
overall effect of lower CD4 cell count (≤100 cell/ mm 3) on log hazard ratio of treatment
failure, while all other predictors held constant.
Also ,  modified the regimen reduces the risk of treatment failure by about  16%  comparing
to those who are not modified the regimen while all other predictors are held constant.
Furthermore an HIV positive patient under second line regimen TDF-3TC-LPV/r was
1.841times higher risk of treatment failure relative to second line regimen ABC-ddI-LPV/r.
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and the risk of treatment failure for AZT-3TC-LPV/r was 2.206 times relative to second line
regimen ABC-ddI-LPV/r, while all other predictors are held constant. Taking INH reduces
the risk of treatment failure by about 37% relatively to not taking INH, while all other
predictors held constant.
Table 10:longitudinal sub model with current value parameterizations and spline-PH-GH
specifications of the baseline risk function from second line ART among adults in Amhara
region (February, 2008 – 2016)
Effects β 95% CI
Intercept 4.499 (4.389    4.608)
Time 0.015 (0.013    0.016)
Gender
Female
Male
0
-0.051 (-0.112   0.011)
ART adherence
Poor
fair
good
0
0.032
0.079
(-0.055   0.120
(0.011   0.148)
CD4 at switch
>100 cells/mm3
≤100cells/mm3
0
-0.966 (-1.035 -0.896)
Regimen
modification
No
Yes
0
0.105 (0.042  0.168)
Variance component
Std. Dev. (intercept) 0.365
Std. Dev. (Time) 0.025
Std.  Dev. (Residual) 0.501
Corr (intercept, slope) -0.010
The interaction effect is added for gender and ART Adherence which are expected that, the
true marker (CD4 cell count) behaves differently (see table 12). A unit increase in the
current value of log CD4 cell count resulted nearly 81 % of reducing treatment failure without
considering gender difference and by nearly 86% for male participants.  Also a unit increase
in the current value of log CD4 cell count resulted nearly 80% of reducing treatment failure
without considering their ART adherence status and by nearly 80% for who had faire ART
Adherence, 87.4% for who had good ART adherence respectively.
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Table 11: survival sub model with current value parameterizations and spline-PH-GH
specifications of the baseline risk function from second line ART among adults in Amhara
region (February, 2008 – 2016)
Effects HR 95% CI(HR)
Gender
Female
male
1
1.179 (0.892   1.556)
ART adherence
Poor
Fair
good
1
1.086
0.948
(0.742   1.589)
(0.705   1.274)
CD4 at switch
>100cells/mm3
≤100 cells/mm3
1
2.795 (1.983   3.939)
Regimen modification
No
Yes
1
0.845 (0.633    1.128)
Second line regimen
ABC-ddI-LPV/r
TDF-3TC-LPV/r
AZT-3TC-LPV/r
Others*
1
1.841
2.760
2.175
(1.182    2.867)
(1.641     4.644)
(1.387    3.409)
Taking INH
No
yes
1
0.631 (0.455   0.876)
Association 0.173 (0.129   0.232)
*= (ABC-ddI-NFV, AZT-3TC-ATV/r, TDF-3TC-ATV/r, ABC-3TC-LPV/r, ABC-3TC-ATV/r)
Table 12: Association parameters with interaction of gender and Adherence from second
line ART among adults in Amhara region (February, 2008 – 2016)
Variables Association Association for interaction
Exp( α) 95%CI (Exp(α) Exp( α) 95%CI (Exp(α)
Gender male 0.192 (0.134 0.274) 0.748 (0.48       1.157)
Fair Adherence
Good Adherence 0.201        (0.138  0.293)
0.956 (0.515     1.775)
0.629 (0.391     1.014)
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Higher association than current value and interaction parameterization was obtained for
lagged parameterization (lagged for six months). A unit increase of true log CD4 count befor
six months resulting nearly 88.5% of reducing treatment failure .(see table 13)
Table 13: Association parameters with lagged effects (for six months) from second line ART
among adults in Amhara region (February, 2008 – 2016)
Association (α) Exp(α) 95%CI(Exp(α))
-2.159 0.115 (0.080   0.165)
4.4 Joint Model Diagnostics
The standard tools to assess the assumptions of joint models are residual plots, which can
be produced by first calculating the specific type of residuals of interest, and then plotting
them against the corresponding fitted values. The subject specific and marginal residuals
versus the corresponding fitted values, the Martingale Residuals Versus Subject-Specific
Fitted values, and Cox Snell residuals were used for model assumption checking (see
annex1, figure 12, 13).
The scatter plot of subject specific and marginal residuals versus the corresponding fitted
values were used to assess the overall goodness of fit test for longitudinal outcome, which
shows the scatter plot is concentrated with zero marginal standardized residuals it indicates
the linear mixed model in joint model was well fitted. The scatter plot of martingale residuals
versus subject-specific fitted values of the log CD4 cell count also shows there is a slight
deviation of the zero martingale residuals and subject-specific fitted values.
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5. Discussions
The main goal of this study was to assess the change in CD4 cell count and time to
treatment failure as well as their risk factors from second line ART among adults in Amhara
region. Joint modeling approach was applied and a significant association (HR=0.173,
95%CI=0.129-0.232) was found between the current unobserved true level of log CD4 cell
count and time to treatment failure.
The average changes of CD4 cell count of HIV patients in ART approximately 50 to 100
cells/mm3 per year until a steady state level is reached (7). The Average rate of change in
CD4 cell count in this study (1.13 cells/ mm3 , mean±SD = -0.03-2.29) per six months was
lower than a studies conducted in Northwest Ethiopia (15, 17). The possible reasons for
this difference might be this study only considers those HIV patients receiving second line
ART and the previous studies consider both first line and second line ART; as a result the
rate of CD4 response may high for those patients under first line.
The median failure time of this study ( 12.93, IQR=7.6-23.50) months was in agreement with
a study conducted in twenty seven African and Asian countries (10). But this result is lower
than a study conducted in western Kenya which is  37 months (IQR = 24 - 47)(29). The
possible reason for this difference might be the previous study was cases –controls and the
study defines cases which are failing first line ART and controls as HIV patients without
failing first line ART, as a result computing the median failure time by merging the cases
and controls might give higher value. The other possible reasons might be difference in
defining the treatment failure, the previous study used WHO 2006 immunological or clinical
failure criteria and the current study used WHO 2016 immunological or clinical failure
criteria.
The incidence rate of treatment failure in this study (9.88, 95%CI=8.7-11) per 100 person
years was higher than a study conducted in northwest Ethiopia (61.7/1000 person
years)(12) and South Eastern Ethiopia (9.38 per 1000 person years) (11). The possible
reasons might be the difference in guideline usage, because the previous study used WHO
guide line 2010 but the current study used WHO guide line 2016.
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In this study HIV positive patients who have good ART Adherence (β=0.079, 95%CI =0.011-
0.148) evolve higher CD4 cell count comparing with those who have poor ART adherence.
This result is in line with a study done in Gondar (17). The possible reason for this result
might be good ART adherence associated with viral load suppression. Also the reason for
this agreement might be similarity in socio economic characteristics, similarity in ART
delivering system of the previous and the current study.
Sex difference was not found as significant predictor of CD4 count change which was in line
a study conducted in northwest Ethiopia (21). In contrast with studies conducted in Uganda,
Tanzania, and Northern Ethiopia (22,30, 31) reported that female HIV patients evolved
higher CD4 cell count than males. The possible reason for this difference might be due to
difference in study design, length of follow up time, methodological difference and the health
seeking behavior might different for males and females of the present study and the
previous study.
Patients who started second line ART at lower CD4 cell count in this study (β=-0.966,
95%CI=-1.035-(-0.896)) evolved lower log CD4 cell count than those who started at higher
CD4 cell count. This was in agreement with a studies conducted in Uganda, (30), North west
Ethiopia (32) and Central Ethiopia(33). The reason for this agreement might be similarity in
social, economical, demographic characteristics of the previous and the current study. The
other possible reason might be similarity in ART delivering system. Also this study founds
patients who started second line ART at lower CD4 cell count((≤100 cells /mm3)
(HR=2.795,95%CI=1.983-3.939) increases the risk of treatment failure which is in
agreement with a study conducted in south eastern Ethiopia, north west Ethiopia, (11-13).
This might be patients with low CD4 count are more prone to different opportunistic
infections.
Adults HIV positive patients in second line ART who modified regimens (β=0.105,
95%CI=0.042-0.168) at least once in the follow up period evolve higher CD4 cell count trend
than who were not modified regimen. The possible reason for this result might be the
modified drug is effective than the previous drug in reducing side effect, drug-drug
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interaction. The other possible reason might be modified regimens for patients experiencing
drug intolerance reconstitute CD4 cell count.
Also this study found that taking INH (HR=0.631, 95%CI=0.455, 0.876) as TB prophylaxis
reduces the risk of treatment failure comparing those who were not take INH keeping other
variables constant. The possible reason for this result might be taking INH reduces the risk
of TB, and reducing the risk of TB also reduces the risk of treatment failure. Furthermore
under second line regimen TDF-3TC-LPV/r(HR=1.841, 95%CI=1.182-2.867), AZT-3TC-
LPV/r (HR=2.76, 95%CI=1.641-4.644) increases the risk of treatment failure comparing
under second line regimen of ABC-ddI-LPV/r held other variables constant.
The study were had both public health and clinical importance. Suppression viral load and
reducing the risk of treatment failure decreases HIV transmission, increases the productivity
of HIV patients and enables maximizing the duration of HIV patients on second line ART.
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Strength and limitation of the study
Strength of the study
The strength of this study was it considers eight far apart Hospitals, had a longer follow-up
period and used advanced model which can fully exploited the association between the
repeated measurement process and the hazard for survival.
Limitation of the study
The limitation of this study was since the source of data was secondary which resulting
incompleteness of information and shortage of relevant literatures.
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6. Conclusion
In conclusion, low increase of average CD4 cell count and higher incidence rate of treatment
failure were obtained from second line ART among adults in Amhara region. Good ART
adherence , modified regimens, CD4 cell count at switch(≤100 cells /mm3) were a significant
predictors for the change of   log CD4 cell count, whereas taking INH, second line
regimenTDF-3TC-LPV/r , second line regimen AZT-3TC-LPV/r , CD4 cell count at
switch(≤100 cells /mm3)  were found a significant predictors of time to treatment failure.
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7. Recommendations
To ART clinics
 Better to give Isoniazid   (INH) for those HIV patients as TB prophylaxes.
 Better to modifying regimens for those HIV patients who develop drug resistance.
 Better to  establish  awareness  and counseling program to improve ART adherence
.
To researchers
 Further studies needed on this topic include other variables that were not included in
this study, such as viral load, Hemoglobin and so many others.
 Better to use joint modeling, because separate analysis does not fully exploit the
association between the repeated measurement process and the hazard for survival
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9. Annexes
Annex1: Additional result
Figure 6: Q-Q plot for normality Assumption checking. (A) Q-Q plot for original CD4 data, (B)
Q-Q plot after transforming the original data in to square root, (C) Q-Q plot after
transforming the original data in to natural logarisim
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Figure 7: Box plots of the original data, transformed to square root and transformed to
natural logarisim
Figure 8: Assessing normality for residuals
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Table 14: Repeated measurements of CD4 cell count per subjects from second line ART
among adults in Amhara region (February, 2008 – 2016)
No. measurements
of CD4 cell count
2 3 4 5 6 7 8 9 10 ≥11
Number of subjects 237 192 159 95 79 71 56 42 72 8
Percent (%) 23.44 18.99 15.73 9.40 7.81 7.02 5.54 4.15 7.12 0.78
Figure 9: Smoothed mean profile for log (CD4) cell count by factor variables  from second
line ART among adults in Amhara region (February, 2008 – 2016). Smoothed mean profile
for log (CD4) cell count by ART adherence (right), Smoothed mean profile for log (CD4) cell
count by second line regimen (left)
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Figure 10: Correlation matrix for log CD4 cell count at each time from second line ART
among adults in Amhara region (February, 2008 – 2016)
Figure 11: Kaplan-Meier survival curve by functional status, Kaplan-Meier survival curve by
second line regimen, Kaplan-Meier survival curve by OIS, Kaplan-Meier survival curve by
TB treatment history given
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Table 15: Number of events in time interval from second line ART among adults in Amhara
region (February, 2008 – 2016)
Time interval
in months
Number
of
events
Percent
(%)
Time interval
in months
Number
of events
Percent
(%)
6-12 114 44.88 36-42 11 4.33
12-18 44 17.32 42-48 8 3.15
18-24 29 11.42 48-54 8 3.15
24-30 16 6.3 ≥54 14 5.51
30-36 10 3.94 Total 254 100
Figure 12: Model diagnosis for longitudinal process (change of log CD4 cell count): subject
specific residuals (left panel), marginal residuals (right panel)
4 5 6 7
-2
-1
0
1
2
Subject specific residuals versus fitted values
Fitted Values
 R
es
id
ua
ls
4 5 6 7
-2
-1
0
1
2
Marginal residuals versus fitted values
Fitted Values
 R
es
id
ua
ls
50
Figure 13: Model diagnostic for survival outcome (time to treatment failure): Martingale
residuals versus the subject-specific fitted values (left panel), Cox-Snell residuals (right
panel)
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Annex2: Information Sheet
Title of the research project: Change in CD4 cell count and time to treatment failure from
second line antiretroviral therapy (ART) among adults in Amhara region: Joint modeling
approach
Principal Investigator–Muluneh Alene (Bsc in statistics)
Advisors
1. Tadesse Awoke (Associate professor)
2. Melaku Kindie (MPH)
Name of the organization: University of Gondar, College of Medicine and Health Sciences,
Institute of Public Heath, Department of Epidemiology and Biostatistics
Sponsor: University of Gondar
Introduction
My name is Muluneh Alene who is post graduate student at University of Gondar for
masters’ degree in public health; I am doing a research to assess the change in CD4 cell
count and time to treatment failure as well as risk factors from second line ART among
adults in Amhara region. This research includes one principal investigator, five data
collectors and three supervisors and two advisors from Gondar University.
Purpose of the Research
This research assess the change in CD4 cell count and time to treatment failure as well as
risk factors from second line ART among adults in Amhara region. Few Studies were
conducted in the Globe and in Ethiopia, on predictors of time to treatment failure and on the
rate of CD4 cell count change. However, there remains to explore more on predictors of
time to treatment failure and on the rate of CD4 cell count change. Also due to
measurement error in the reapted measurement and informative dropout, separate analysis
does not fully exploit the association between the repeated measurement process and the
hazard for survival. Thus the motivation of this study is to analyze jointly repeated
measurements of biomarkers (CD4 cell count) and time to treatment failure with their
associated factors from second line ART among Adults in Amhara region.
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Confidentiality and Anonymity
The information that I collect for this research was kept confidential. Information about study
subjects that will be collected during the research will be stored in a file, which will not write
the name or any personality identification.
Benefits: The study subject not get direct benefit, but the participation is likely to help us to
assess the change in CD4 cell count and time to treatment failure .In addition finally, it will
give an insight for policy makers and programmers to design new interventions.
Risk and/or discomfort
Since the source of data is secondary, the research not imposes any risk or discomfort.
Persons to contact
Contact addresses below:
1. Muluneh Alene
Tel: +251922894376                               E-mail: mulunehadis@gmail.com
2. Tadesse Awoke (Associate professor)
Tel: +251910173308                               E-mail: tawoke7@gmail.com
3. Melaku Kindie (MPH)
Tel: +251913002871                                E-mail: melaku98@gmail.com
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Annex3: Data collection Check list
This checklist is prepared for the collection of  both baseline and follow up socio-
demographic, clinical, immunological, treatment and outcome related information that are
important for the assessment of CD4 cell count Change and time to treatment failure from
second line antiretroviral therapy (ART) among adults in University of Gondar Hospital,
FelegeHiwot referral Hospital, Debremarkos hospital, Dessee referral hospital, Debre Tabor
Hospital, Finote-Selam Hospital, Debrebirhan referral Hospital and Woldiya Hospital.
Information was retrieved from the clients ART and pre-ART registration book and from
individual patient card without mentioning the name of clients. This information was
collected by health care providers (BSc nurse or Health Officer) possibly working in the ART
clinic of the hospitals.
Contact Information
Muluneh Alene Tel +251-922894376
Mr.Tadesse Awoke Tel +251-910-173308
Mr.Melaku Kindie Tel +251-90913002871
Part I: Baseline variables
S.
No
Variables Categories
1 Hospital/Facility
2 Patient MRN
number
3 Patient-ART
number
4 Age at
enrollment
5 Date of
enrollment
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6 Gender 1 Female 2 Male
7 Address Zone____    Woreda_ Kebele___
8 Marital status 1.Single        2.Married     3.Divorced   4.Widowd    5.Separated
9 Education 1.No education 2.Elementary 3 .Secondary 4.Tertiary
10 Occupation 1. Unemployed     2.Government   3.Nongovernment   4. Private
4.Other
11 Past
opportunistic
infections
1.  Yes              2. No         If yes,    Specify ____
12 Past TB
treatment
history
1. Yes      2. No           3. Not recorded
13 Is the treatment
completed?
1. Yes 2.  No
14 Substance use 1 Tobacco      2. Alcohol          3. Khat        4. None
15 Baseline
Weight
______kg
16 Baseline  Height ________m
17 Base line CD4 -------
18 Baseline WHO
stage
1. Stage I      2. Stage II    3. Stage III   4. Stage IV
19 Baseline
Functional
status
1. Working        2. Ambulatory          3. Bedridden
20 Base  line
hemoglobin
21 ART start date
22 Reasons of
eligibility for
ART
1. Clinical   2. CD4 count  3.Viral load  4.TLC 5.Transfer in
6. Other
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23 Original regimen 1. 1a
2. 1b
3. 1c
4. 1d
5. 1e
6. 1f
7. 1g
8. 1h
9.1i
10.1j
24 Was the
Regimen
modified before
switch to
second line
changed?
1. Yes 2. No
25 How many
times it
modified?
1. Once 2. Two
times
3. Three
times
26 When was it
changed
1. 1st---/--/-- 2. 2nd---/- 3. 3rd---/--
27 New regimen 1. 1st_____ 2. 2nd___ 3. 3rd___
28 Reason for
modification
1st 1. Side
effects
2. TB 3. Pregnan
cy
4. Others
------
2nd 1. Side
effects
2. TB 3. Pregnan
cy
4. Others
------
3rd 1. Side
effects
2. TB 3. Pregnan
cy
4. Others
------
29 Date  the
regimen
changed to
second line
-----/-----/-------- (DD/MM/YY)
30 Second line
regimen
1. 2a
2. 2b
3. 2c
4. 2d
5. 2e
6. 2f
7. 2g
8. 2h
9. 2i
10.Oth
er
31 Reason for 1. Clinical 2. Immun 3. Virolo 4. Drug 5. Other(s
56
switch failure ologic
failure
gic
failur
e
toxicity pecify
32 T stage at
switch
1. T stage 1          2.T stage 2            3.Tstage 3                   4.T stage 4
33 Viral load at
switch
1. Undetectable(<400
cell/ml)
2. 400-10,000c/ml 3. >10,00
0c/ml
4. Not
done
34 Second line Rx
failure
1.yes 2.no
36 Was the
Regimen
modified
4. Yes 2. No If No go
to III
37 How many
times it
modified?
4. Once 5. Two times 6. Three
times
38 When was it
modified
1. 1st---/--/------ 2nd---/--/---- 3rd---/--/------
39 New regimen 1. 1st_____ 2. 2nd_____ 3. 3rd___
40 Reason for
modification
1. Side effects     2.TB            3.Pregnancy                 4.Others
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Part II: Follow-up variables after switch to second line ART
Date of
second
line
follow
up
Wei
ght
Fun
ctio
nal
Sta
tus
WH
O
sta
ge
TB
scr
een
O
Is
IN
H
CPT
/Adh
e(G,
F,P)
ARV drug Last Status
Adhe
renc
e
C
od
e 
of
 re
gi
m
en
Regi
men
chan
ge(Y/
N)
R.
for
cha
ng
e
Sid
e
effe
ct
He
mog
lobi
n
level
C
D
4
c
o
u
nt
B
M
I
Al
iv
e
D
ea
d
D
ro
p 
ou
t
Tr
an
sf
er
 o
ut
Collected by: Name __________________Signature ____________Date
Supervised by: Name ____________________signature ________Date
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